Skip to content

PREDICTOM Level 2 Clinical Study has started

The PREDICTOM is pleased to announce the launch of Level 2 of its international clinical study—an important next step made possible entirely through the generosity, time, and commitment of participants across Europe. The participants' contributions continue to drive forward our shared goal: improving the early detection of Alzheimer’s disease through accessible, reliable, and science-driven tools.

Published 5 March 2026

What is included in Level 2 testing?

Level 2 brings participants back to the clinic for a comprehensive series of assessments designed to capture a deeper understanding of biological, cognitive, and neurological markers. Based on the study plan, participants will complete:

  • Cognitive and functional assessments: Montreal Cognitive Assessment (MoCA), informant-completed ADL questionnaires

  • Clinical and neurological exams: Medical history review, physical and neurological examinations, vital signs

  • Bio-sample collection: Venous blood draw, stool/saliva/fingerprick kits, and cerebrospinal fluid collection via lumbar puncture

  • Neurophysiological and imaging tests: Electroencephalography (EEG), two MRI brain scans or PET scans

  • Sensory assessments: Eye-tracking and hearing tests

  • At‑home elements: RUD‑Lite

These assessments are carefully selected to provide a well-rounded view of the early changes associated with Alzheimer's disease.

Photo: colourbox.com

How are participants selected for Level 2?

Participants are invited using research-based criteria such as completeness of initial study data, ensuring diversity across age and demographic factors, and practical considerations. Importantly, an invitation to Level 2 does not indicate anything about a participant’s dementia risk and has no diagnostic significance.

How long does Level 2 take?

Level 2 activities take place across three full study days (in estimation), spread over approximately six weeks. Scheduling is flexible, depending on available resources and time slots, participants will be given opportunities to choose appointment times that fit their availability. A brief follow-up phone call is completed after the lumbar puncture to ensure participant well‑being.

PS: The exact timing for each assessment varies among participants.

– Day 1 (≈4 hours): Cognitive testing, clinical exams, EEG, sensory tests, blood collection, bring-home biofluid kits

– Day 2 (≈2 hours 40 minutes): Return biofluid kits, MRI scans

– Day 3 (≈4 hours): Lumbar puncture and rest period

– Post‑visit: 15‑minute safety phone call

A Shared Effort Toward Better Care

We extend our heartfelt thanks to every participant who has supported PREDICTOM so far. Your involvement brings us closer to a future where Alzheimer’s disease can be identified earlier, treated more effectively, and understood in greater depth. Level 2 is an exciting and meaningful next step—and it would not be possible without you.

Click here to see our clinical study progress

Latest news

PREDICTOM Highlights the Power of Partnership and Public Involvement at Alzheimer Europe Conference 2026

News

PREDICTOM Highlights the Power of Partnership and Public Involvement at Alzheimer Europe Conference 2026

At the 36th Alzheimer Europe Conference in Dublin, the PREDICTOM sponsored session opened with a video message from Dr. Niklas Blomberg, Executive Director of the Innovative Health Initiative (IHI). His remarks placed PREDICTOM within the broader mission of IHI and underscored two key ingredients for successful health innovation: meaningful patient and public involvement, and strong partnerships across sectors.

Read more
AI-Powered Screening Tool Helps Identify People at Higher Risk of Dementia

News

AI-Powered Screening Tool Helps Identify People at Higher Risk of Dementia

An innovative AI-powered screening gatekeeper could help transform how dementia risk is assessed. Researchers from the European PREDICTOM project have developed a risk stratification pipeline that combines established risk factors and cognitive performance data to identify people most likely to benefit from further investigation, helping target costly tests where they are needed most.

Read more
Home-Based Alzheimer's Blood Testing Shows Promise, but Collecting Quality Samples Remains a Challenge

News

Home-Based Alzheimer's Blood Testing Shows Promise, but Collecting Quality Samples Remains a Challenge

Could older adults one day participate in Alzheimer's screening without leaving home? Researchers behind the European PREDICTOM project are exploring that possibility through remote blood collection, but new findings suggest that the biggest hurdle may be getting a good blood sample in the first place.

Read more